JXJinhua Xu

Jinhua Xu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jinhua Xu has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Copper (II) complex of salicylate phenanthroline induces the apoptosis of colorectal cancer cells, including oxaliplatin‑resistant cells

    by Zixin Liu, Limei Fan, Dongqin Niu, Ming Chen, Weiran Zhang, Yuchen Liu, Jinhua Xu, Dong Wang

    Oxaliplatin (Oxa) is one of the most effective chemotherapeutic drugs used in the treatment of colorectal cancer (CRC). However, the use of this drug is associated with severe side‑effects and patients eventually develop resistance to Oxa. In recent years, copper complexes have been extensively investigated as substitutes for platinum‑based drugs. Therefore, a number of copper complexes have also been developed for cancer therapy, such as copper (II) complex of salicylate phenanthroline [Cu(sal)(phen)]. In the present study, the antitumor activity and the related molecular mechanisms of Cu(sal)(phen) were examined in CRC cells. As compared with the chemotherapeutic drug, Oxa, Cu(sal)(phen) was more effective in inducing apoptosis and reactive oxygen species (ROS) production, and in decreasing mitochondrial membrane potential in the CRC cell lines, HCT116 and SW480. In addition, the expression of the apoptosis‑related proteins, Bcl‑2 and survivin, and those of the upstream regulators, p‑JAK2 and p‑STAT5, were significantly decreased in the two cell lines following treatment with Cu(sal)(phen). Furthermore, the efficacy of the complex against CRC was found to be excellent in an animal model. The results of immunohistochemical analysis revealed that the expression levels of Bcl‑2, survivin and Ki‑67 in tumor tissues were decreased following Cu(sal)(phen) treatment. The antitumor mechanisms underlying Cu(Sal)(phen) treatment were the induction of ROS generation, the inhibition of the JAK2/STAT5 signaling pathway and the downregulation of the expression of anti‑apoptotic proteins, such as Bcl‑2 and survivin. On the whole, the findings of the present study indicated that Cu(sal)(phen) effectively inhibited the viability and proliferation of HCT116 and SW480 CRC cells; in the future, the authors aim to conduct further experiments in future studies to provide more evidence that supports the development of Cu(sal)(phen) as a therapeutic agent for CRC.


  • Open Access

    Zinc complex of 3,5-di-tert-butyl salicylate inhibits viability, migration, and invasion in triple-negative breast cancer cells

    by Heng Chen, Dong Wang, Limei Fan, Zixin Liu, Weiran Zhang, Jinhua Xu, Yunyi Liu

    The zinc complex of 3,5-di-tert-butyl salicylate (Zn{[CH3)3C]2Sal}22−) is a zinc ion chelate of salicylate. In this study, we found that this compound inhibits viability, invasion, and migration and induces apoptosis in triple-negative breast cancer 4T1 cells. RNA-seq showed that the expression of 17 genes was upregulated and 26 genes were downregulated significantly by Zn{[CH3)3C]2Sal}22− treatment. Further GO and KEGG analysis showed that the activity of Zn{[CH3)3C]2Sal}22− against triple-negative breast cancer cells may be involved in the JAK-STAT3, HIF-1, and TNF signaling pathways. The expression of key genes was verified by RT–PCR. The phosphorylation of STAT3 and its upstream SRC decreased drastically upon Zn{[CH3)3C]2Sal}22− treatment, as demonstrated by western blot. Our results indicate that Zn{[CH3)3C]2Sal}22− inhibits the activity of TNBC cells by downregulating the STAT3 signaling through the SRC pathway.


  • Open Access

    Salicylate •Phenanthroline copper (II) complex induces apoptosis in triple-negative breast cancer cells

    by Limei Fan, Muyou Tian, Yunyi Liu, Ying Deng, Zhengkai Liao, Jinhua Xu

    Salicylate •Phenanthroline copper (II) complex induces apoptosis in triple-negative breast cancer cells


  • β-catenin regulatesc-MycandCDKN1Aexpression in breast cancer cells

    by Jinhua Xu, Yinghua Chen, Dezheng Huo, Andrey Khramtsov, Galina Khramtsova, Chunling Zhang, Kathleen H. Goss, Olufunmilayo I. Olopade

    We previously reported that the Wnt pathway is preferentially activated in basal‐like breast cancer. However, the mechanisms by which the Wnt pathway regulates down‐stream targets in basal‐like breast cancer, and the biological significance of this regulation, are poorly understood. In this study, we found that c‐Myc is highly expressed in the basal‐like subtype by microarray analyses and immunohistochemical staining. After silencing β‐catenin using siRNA, c‐Myc expression was decreased in non‐basal‐like breast cancer cells. In contrast, c‐Myc mRNA and protein expression were up‐regulated in the basal‐like breast cancer cell lines. Decreased c‐Myc promoter activity was observed after inhibiting β‐catenin by siRNA in non‐basal‐like breast cancer cells; however, inhibition of β‐catenin or over‐expression of dominant‐negative LEF1 had no effect on c‐Myc promoter activity in basal‐like breast cancer cell lines. In addition, CDKN1A mRNA and p21 protein expression were significantly increased in all breast cancer cell lines upon β‐catenin silencing. Interestingly, inhibiting β‐catenin expression alone did not induce apoptosis in breast cancer cell lines despite c‐Myc regulation, but we observed a modest increase of cells in the G1 phase of the cell cycle and decrease of cells in S phase upon β‐catenin silencing. Our findings suggest that the regulation of c‐Myc in breast cancer cells is dependent on the molecular subtype, and that β‐catenin‐mediated regulation of c‐Myc and p21 may control the balance of cell death and proliferation in breast cancer.


  • Open Access

    β-Catenin Is Required for the Tumorigenic Behavior of Triple-Negative Breast Cancer Cells

    by Jinhua Xu, Jenifer R. Prosperi, Noura Choudhury, Olufunmilayo I. Olopade, Kathleen H. Goss

    Our previous data illustrated that activation of the canonical Wnt signaling pathway was enriched in triple-negative breast cancer and associated with reduced overall survival in all patients. To determine whether Wnt signaling may be a promising therapeutic target for triple-negative breast cancer, we investigated whether β-catenin was necessary for tumorigenic behaviors in vivo and in vitro. β-catenin expression level was significantly reduced in two human triple-negative breast cancer cell lines, MDA-MB-231 and HCC38, using lentiviral delivery of β-catenin-specific small hairpin RNAs (shRNAs). Upon implantation of the cells in the mammary fat pad of immunocompromised mice, we found that β-catenin shRNA HCC38 cells formed markedly smaller tumors than control cells and grew much more slowly. In in vitro assays, β-catenin silencing significantly reduced the percentage of Aldefluor-positive cells, a read-out of the stem-like cell population, as well as the expression of stem cell-related target genes including Bmi-1 and c-Myc. β-catenin-knockdown cells were also significantly impaired in their ability to migrate in wound-filling assays and form anchorage-independent colonies in soft agar. β-catenin-knockdown cells were more sensitive to chemotherapeutic agents doxorubicin and cisplatin. Collectively, these data suggest that β-catenin is required for triple-negative breast cancer development by controlling numerous tumor-associated properties, such as migration, stemness, anchorage-independent growth and chemosensitivity.